Biofrontera (BFRIW) Stock Price, News & Analysis

Company Overview

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.02 to $0.19
• 52-Week Range: $0.01 to $0.23
• Volume: 1,871 shs
• Average Volume: 11,871 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BFRIW Stock Analysis - Frequently Asked Questions

How have BFRIW shares performed this year?

Biofrontera's stock was trading at $0.01 at the start of the year. Since then, BFRIW shares have increased by 539.0% and is now trading at $0.0639.
View the best growth stocks for 2024 here.

How do I buy shares of Biofrontera?

Shares of BFRIW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BFRIW
• CUSIP: N/A
• CIK: 1858685
• Web: www.biofrontera-us.com
• Phone: 781-245-1325
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $35.36 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A